Skip to main content
ReproCELL Incorporated logo

ReproCELL Incorporated — Investor Relations & Filings

Ticker · 4978 ISIN · JP3974770004 LEI · 529900NM7KR32GGRSU46 T Professional, scientific and technical activities
Open in API
Filings indexed 63 across all filing types
Latest filing 2026-05-27 Share Issue/Capital Cha…
Country JP Japan
Listing T 4978

About ReproCELL Incorporated

https://www.reprocell.com/

ReproCELL Incorporated is a global company providing solutions for preclinical and clinical research, with a primary focus on stem cell technology, drug discovery, and regenerative medicine. The company's portfolio includes a wide range of products such as induced pluripotent stem cells (iPSCs), differentiated cells, 3D cell culture models, and specialized reagents like RNA-based reprogramming kits that avoid genomic integration. ReproCELL also offers extensive contract research services, including human tissue assays for evaluating drug efficacy and safety. A key area of expertise is the GMP-compliant manufacturing of clinical-grade iPSCs and iPSC-derived mesenchymal stem cells (iMSCs), supporting the development of advanced cell therapies. The company's tools and services are designed to help academic and commercial scientists accelerate the translation of research into clinical applications.

Recent filings

Filing Released Lang Actions
株式及び新株予約権発行プログラム設定契約締結に係る発行登録並びに第三者割当による新株式及び新株予約権の発行に関するお知らせ
Share Issue/Capital Change Classification · 90% confidence The document is a detailed disclosure of a third-party allotment of common shares and stock acquisition rights under an equity program agreement, including issuance registration details, number of shares, pricing, allotment schedule, and conditions. This is a specific announcement of new share issuance and capital structure change, matching the definition for Share Issue/Capital Change (Code: SHA).
2026-05-27 Japanese
連結子会社（REPROCELL USA Inc.）に対する補助金の交付決定に関するお知らせ
Regulatory Filings Classification · 60% confidence The document is a formal stock‐exchange filing by a Japanese company announcing that its U.S. subsidiary has been awarded a government grant. It contains no financial statements, no change of directors, no share issuance or debt, and is not an earnings release or investor presentation. It is a general regulatory announcement (press release) to shareholders and the market. Therefore, it is best classified as a Regulatory Filing (RNS).
2026-05-22 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly cites '金融商品取引法第24条の５の２第１項' (Article 24-5-2, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification regarding the accuracy of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS) rather than the report itself. H1 24
2025-11-13 Japanese
半期報告書－第24期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by ReproCELL Incorporated under the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, management analysis (MDA), and business performance data for the interim period (April 1, 2025, to September 30, 2025). This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2025
2025-11-13 Japanese
内部統制報告書－第23期(2024/04/01－2025/03/31)
Audit Report / Information Classification · 95% confidence The document is titled "内部統制報告書" (Internal Control Report) and explicitly cites the legal basis as "金融商品取引法第24条の４の４第１項" (Financial Instruments and Exchange Act Article 24-4-4, Paragraph 1). This structure and content—detailing the framework, scope, criteria, and conclusion regarding the effectiveness of internal controls over financial reporting as of a specific fiscal year-end (March 31, 2025)—is characteristic of the internal control report required under Japanese securities law, which is analogous to the Sarbanes-Oxley Section 404 report in the US context. While there isn't a direct 1:1 mapping in the provided codes, the closest fit for a comprehensive, standalone report detailing internal control effectiveness, which is often filed alongside the annual report but is distinct, is the Audit Report/Information (AR) category, as it deals with assurance and control testing results. However, given the specific nature of this document being solely the Internal Control Report (which is a mandatory component of the annual filing process in Japan, similar to the US 10-K), and lacking a specific 'Internal Control Report' code, 'AR' (Audit Report / Information) is the most appropriate classification among the choices for a formal, assurance-related document that is not the full Annual Report (10-K) or a simple Earnings Release (ER). The document is substantial and detailed, ruling out RPA or RNS based on the 'MENU VS MEAL' rule. FY 2025
2025-06-26 Japanese
確認書
Audit Report / Information Classification · 98% confidence The document text contains Japanese regulatory headers, specifically mentioning "有価証券報告書" (Yuka Shoken Hokokusho), which translates to 'Securities Report' or 'Annual Securities Report'. It also references the Financial Instruments and Exchange Act ("金融商品取引法") and lists the submission date, company name, and responsible officers confirming the appropriateness of the report's contents for the fiscal year ending March 31, 2025. In the context of US SEC filings, the closest equivalent to a comprehensive annual securities report is the 10-K. Given the context of a comprehensive annual filing confirming its accuracy, the classification should align with the Annual Report category (10-K), even though the specific Japanese document type is slightly different from the US 10-K form. The document is the report itself, not an announcement of the report's release, and it is comprehensive, not just highlights (ruling out ER). FY 2025
2025-06-26 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.